Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

被引:269
作者
Berger, C
Flowers, ME
Warren, EH
Riddell, SR
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Seattle, WA 98195 USA
关键词
D O I
10.1182/blood-2005-08-3503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of an inducible suicide gene such as the herpes simplex virus thymidine kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after allogeneic hematopoietic cell transplantation (HCT) without graft versus host disease. However, HSV-TK is foreign, and immune responses to gene-modified T cells could lead to their premature elimination. We show that after the infusion of HSV-TK-modified donor T cells to HCT recipients, CID8(+) and CD4(+) T-cell responses to HSV-TK are rapidly induced and coincide with the disappearance of transferred cells. Cytokine flow cytometry using an overlapping panel of HSV-TK peptides allowed rapid detection and cluantitation of HSV-TK-specific T cells in the blood and identified multiple immunogenic epitopes. Repeated infusion of modified T cells boosted the induced HSV-TK-specific T cells, which persisted as memory cells. These studies demonstrate the need for nonimmunogenic suicide genes and identify a strategy for detection of CD4(+) and CD8(+) T-cell responses to transgene products that should be generally applicable to monitoring patients on gene therapy trials. The potency of gene-modified T cells to elicit robust and durable immune responses imply this approach might be used for vaccination to elicit T-cell responses to viral or tumor antigens.
引用
收藏
页码:2294 / 2302
页数:9
相关论文
共 56 条
  • [21] THYMIDINE KINASE OBLITERATION - CREATION OF TRANSGENIC MICE WITH CONTROLLED IMMUNE-DEFICIENCY
    HEYMAN, RA
    BORRELLI, E
    LESLEY, J
    ANDERSON, D
    RICHMAN, DD
    BAIRD, SM
    HYMAN, R
    EVANS, RM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) : 2698 - 2702
  • [22] HIGANO CS, 1992, BLOOD, V80, P1437
  • [23] Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation
    Higano, CS
    Chielens, D
    Raskind, W
    Bryant, E
    Flowers, MED
    Radich, J
    Clift, R
    Appelbaum, F
    [J]. BLOOD, 1997, 90 (07) : 2549 - 2554
  • [24] HOROWITZ MM, 1990, BLOOD, V75, P555
  • [25] Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies
    Introna, M
    Barbui, AM
    Bambacioni, F
    Casati, C
    Gaipa, G
    Borleri, G
    Bernasconi, S
    Barbui, T
    Golay, J
    Biondi, A
    Rambaldi, A
    [J]. HUMAN GENE THERAPY, 2000, 11 (04) : 611 - 620
  • [26] Inhibition of death receptor signals by cellular FLIP
    Irmler, M
    Thome, M
    Hahne, M
    Schneider, P
    Hofmann, B
    Steiner, V
    Bodmer, JL
    Schroter, M
    Burns, K
    Mattmann, C
    Rimoldi, D
    French, LE
    Tschopp, J
    [J]. NATURE, 1997, 388 (6638) : 190 - 195
  • [27] Graft-versus-leukemia reactions in allogeneic chimeras
    Kolb, HJ
    Schmid, C
    Barrett, AJ
    Schendel, DJ
    [J]. BLOOD, 2004, 103 (03) : 767 - 776
  • [28] GRAFT-VERSUS-LEUKEMIA EFFECT OF DONOR LYMPHOCYTE TRANSFUSIONS IN MARROW GRAFTED PATIENTS
    KOLB, HJ
    SCHATTENBERG, A
    GOLDMAN, JM
    HERTENSTEIN, B
    JACOBSEN, N
    ARCESE, W
    LJUNGMAN, P
    FERRANT, A
    VERDONCK, L
    NIEDERWIESER, D
    VANRHEE, F
    MITTERMUELLER, J
    DEWITTE, T
    HOLLER, E
    ANSARI, H
    [J]. BLOOD, 1995, 86 (05) : 2041 - 2050
  • [29] Kornblau SM, 2001, CANCER RES, V61, P3355
  • [30] Suicide genes: past, present and future perspectives
    Lal, S
    Lauer, UM
    Niethammer, D
    Beck, JF
    Schlegel, PG
    [J]. IMMUNOLOGY TODAY, 2000, 21 (01): : 48 - 54